Herein, we propose that a rapid adaptive signaling response following MAPKi administration can direct an increase in expression of the immunosuppressive protein CD73 as well as decrease the sensitivity to the MAPKis in a subset of breast cancer and melanoma patients and in various cell lines from different cancers. Here, NT5E is linked to breast cancer.